Haematologica (Feb 2019)

CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies

  • Lucia Prieto-Torres,
  • Socorro M. Rodriguez-Pinilla,
  • Arantza Onaindia,
  • Mariano Ara,
  • Luis Requena,
  • Miguel Á. Piris

DOI
https://doi.org/10.3324/haematol.2018.197152
Journal volume & issue
Vol. 104, no. 2

Abstract

Read online

Primary cutaneous CD30-positive T-cell lymphoproliferative disorders are the second most common subgroup of cutaneous T-cell lymphomas. They include two clinically different entities with some overlapping features and borderline cases: lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. Molecular studies of primary cutaneous anaplastic large cell lymphoma reveal an increasing level of heterogeneity that is associated with histological and immunophenotypic features of the cases and their response to specific therapies. Here, we review the most significant genetic, epigenetic and molecular alterations described to date in primary cutaneous CD30-positive T-cell lymphoproliferative disorders, and their potential as therapeutic targets.